Evozyne CEO Marc Yoskowitz is a veteran biopharma executive known for leading public and private companies through transformative periods of growth. Prior to joining Evozyne, Yoskowitz was chief strategy officer and executive vice president of life sciences at Tempus AI. He has held executive leadership positions with Pfizer, Hospira and McKinsey & Company. Yoskowitz has […]
Arjun Rallapalli is focused on developing Evozyne’s overall strategy by identifying new markets, solutions, and services for the company’s proprietary technology and implementing the strategy through business development and partnerships. Before Evozyne, Rallapalli was a manager at McKinsey & Company, where he led strategy engagements across different sectors. He began his career at GE Healthcare […]
Uri Herzberg has extensive expertise in drug discovery with companies including Johnson & Johnson, Celgene, Cabaletta Bio, Celularity and Fresh Tracks Therapeutics. His expertise encompasses preclinical development, translational research, regulatory strategy, early clinical trial design target identification and indication selection. He holds a doctorate in veterinary medicine, a PhD in veterinary biology and neuroimmunology and […]
Stephen Wanaski, Ph.D., is senior vice president of research and exploratory development at Evozyne, overseeing basic science, pharmacology and toxicology, clinical pharmacology, and scientific due diligence. Dr. Wanaski is an experienced drug development leader with a track record in orphan drug development of small and large molecules from discovery through late-stage clinical studies and FDA […]
